Skip to content
DataLookout
Menu

INVICTUSNCT07675018

INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Primary and study completion dates: Sep 21, 2028 to Sep 26, 2028
    • Start date changed from estimate of Sep 15, 2026 to Sep 20, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised at 7 of 7 sites
  2. Minor Study description shortened, about 7 words
    • Study title shortened, about 3 words
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of days with large broad-spectrum antibiotic therapy
Timeframe: Day 7

Secondary (4)

Proportion of patients with clinical resolution of UTI
Proportion of patients for whom the empirical antibiotic therapy
Proportion of patients, for whom the integron detection result was consistent with the AST
Proportion of resistant bacteria for the clinically-relevant antibiotics

Arms and interventions

Empirical parenteral antibiotic therapy based on the detection of integronsExperimental

In the experimental arm, empirical parenteral antibiotic therapy will be guided based on the detection of integrons. If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed. If integrons detection is negative, patient will receive a parenteral 3GC (ceftriaxone, cefotaxime, ceftazidime or cefepime). The treatment will be started after the integron detection

Empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinationsActive comparator

In the control arm, the comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion. The treatment will be started after the randomization

Diagnostic tests: Detection of integrons

Other: Gold standard

Sites

7 sites in 1 country